Trials / Unknown
UnknownNCT03742492
Bioavailability of EPA + DHA Enriched Canned Tuna and Its Acute Effects
Bioavailability of EPA + DHA Enriched Canned Tuna and Its Acute Effects on Cardiovascular Risk Markers, in Healthy Human Volunteers
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Universidade do Porto · Academic / Other
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
Evidence has suggested that omega-3 fatty acids, namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have an important role in promoting cardiovascular health. However, the currently available scientific literature describing the postprandial effects and bioavailability of these fatty acids, particularly when they are incorporated into high protein food item, like canned tuna, is far from conclusive. The aim of this study is to evaluate the acute bioavailability of EPA + DHA enriched canned tuna and its acute effects on cardiovascular risk markers, in healthy human volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Meal containing canned tuna + fish oil (5 g EPA + DHA) | Meal containing canned tuna + fish oil (5 g EPA + DHA) |
| DIETARY_SUPPLEMENT | Meal containing canned tuna + soybean oil | Meal containing canned tuna + soybean oil |
Timeline
- Start date
- 2018-09-19
- Primary completion
- 2019-06-01
- Completion
- 2019-07-01
- First posted
- 2018-11-15
- Last updated
- 2019-05-30
Locations
1 site across 1 country: Portugal
Source: ClinicalTrials.gov record NCT03742492. Inclusion in this directory is not an endorsement.